. 2011 Jul 13;3:257–266. doi: 10.2147/CMR.S12713

Table 3.

Targeted therapies in metastatic gastric cancer: current results

	Phase	n	Regimen	RR (%)	PFS (m)	OS (m)
Bang et al³⁷	III	298/296	Tr-C-5-FU/C-5FU	47/35 (P = 0.0017)	6.7/5.5 (P = 0.0002)	13.8/11.1 (P = 0.0046)
Kang et al³⁸	III	387/387	B-C-5-FU/C-5FU	38/29.5 (P = 0.0121)	6.7/5.3 (P = 0.0037)	12.1/10.1 (NS)
El-Rayes et al³⁹	II	38	B-O-D	42	6.6	11.1
Sun et al⁴⁰	II	44	Sor-C-D	41	5.8	13.5

Abbreviations: n, number of patients; RR, response rate; TTF, time to treatment failure; PFS, progression free survival; OS, overall survival; Tr, trastuzumab; C, cisplatin; 5-FU, 5-fluorouracil; B, bevacizumab; O, oxaliplatin; D, docetaxel, Sor, sorafenib.